A Study for Efficacy and Safety of Live Biotherapeutic MRx4DP0004 to Treat COVID-19

Summary

This is a randomised, double-blind, placebo controlled study to evaluate the efficacy and safety of MRx-4DP0004 in patients with COVID-19. 90 hospitalised patients will be enrolled and randomised (2:1) to receive MRx-4DP0004 or placebo for up to 14 days. MRx-4DP0004 is an immunomodulating Live Biotherapeutic Product (LBP) which is expected to prevent or reduce the hyperinflammatory response to SARS-CoV-2 infection without impairing viral clearance.

Timeline

Start

2020-08

Primary completion

2020-12

Completion

2021-01

Outcome

Outcome not reported

Stopped (Enrollment): “Recruitment Issues”

Drugs

Indications